Sun Pharma gains 3% on USFDA approval for psoriasis drug Ilumya
Ilumya is used for the treatment of the most common plaque psoriasis – a chronic immune disease that appears on the skin. Shares of Sun Pharmaceutical Industries gained 3.4 percent in the early trade on Thursday as it has received USFDA approval for its psoriasis drug Ilumya. To Get Free Trial Missed call @ 9582541010 Call Us @ 8822117117 …
Comments
Log in to comment or register here .